The Latest Cardiac and Vascular News
IRVINE, Calif., June 1, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that Acumen Hypotension Prediction Index (HPI) software with the Acumen IQ finger cuff has received U.S. Food and Drug Administration clearance. This is the first noninvasive solution that unlocks Acumen HPI software and uses machine learning to alert clinicians of the […]
At 1 year, outcomes similar to overall cohort of patients IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and […]
IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company’s transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease. The clinical data presentations […]
AUSTIN, Texas, Jan. 31, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards’ bioprosthetic surgical aortic valve with the company’s novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median of five years follow-up. The data were presented at the […]
IRVINE, Calif., Jan. 27, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2020. Fourth Quarter Highlights and Outlook Q4 sales increased 1 percent to $1.2 billion; underlying1 sales flat Q4 TAVR sales grew 2 percent; underlying sales flat Q4 EPS was $0.49; adjusted1 EPS grew 2 percent to $0.50 December […]
IRVINE, Calif., Dec. 21, 2020 /PRNewswire/ — Edwards Lifesciences (NYSE: EW), today announced that the first patient has been treated in the RESTORE clinical trial, which will evaluate the safety and effectiveness of the investigational HARPOON Beating Heart Mitral Valve Repair System in the United States and Canada. The HARPOON system uses a less-invasive technique than open-heart […]
IRVINE, Calif., Dec. 10, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance today during its annual investor conference. Highlights1 of today’s conference include: Presenting long-term strategic initiatives and growth outlook Projecting 2021 global sales […]
IRVINE, Calif., Oct. 21, 2020 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2020. Third Quarter Highlights and Outlook Sales of $1.1 billion grew 4%; similar underlying1 growth expected in the fourth quarter TAVR global sales grew 6% EPS was $0.52; adjusted1 EPS grew 9% to $0.51 TMTT clinical trials now enrolling […]
Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients DUBLIN, Oct. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced it will begin a randomized, head-to-head study comparing two transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic […]
IRVINE, Calif., July 23, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2020. Second Quarter Highlights and Outlook Sales declined 15% to $925 million; underlying1 sales declined 14% TAVR sales declined […]
